Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Status:
RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).
Phase:
PHASE1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute